| Year |
Citation |
Score |
| 2022 |
Dawes C, Quinn D, Bickerdike A, O'Neill C, Granger KT, Pereira SC, Mah SL, Haselgrove M, Waddington JL, O'Tuathaigh C, Moran PM. Latent inhibition, aberrant salience, and schizotypy traits in cannabis users. Schizophrenia Research. Cognition. 28: 100235. PMID 35028297 DOI: 10.1016/j.scog.2021.100235 |
0.479 |
|
| 2021 |
Granger KT, Ferrar J, Caswell S, Haselgrove M, Moran PM, Attwood A, Barnett JH. Effects of 7.5% Carbon Dioxide and Nicotine Administration on Latent Inhibition. Frontiers in Psychiatry. 12: 582745. PMID 33935819 DOI: 10.3389/fpsyt.2021.582745 |
0.65 |
|
| 2019 |
Cotter J, Barnett JH, Granger K. The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia. Frontiers in Psychiatry. 10: 648. PMID 31551837 DOI: 10.3389/Fpsyt.2019.00648 |
0.438 |
|
| 2019 |
Granger K, Cotter J, Baker E, Barnett J, Sand M. 32.3 A Post-Hoc Analysis Exploring Participant-Level Trajectories Of Cognitive Performance Among Patients With Schizophrenia In A Multi-National Phase Ii Trial Schizophrenia Bulletin. 45. DOI: 10.1093/Schbul/Sbz022.134 |
0.404 |
|
| 2019 |
Barnett J, Ferrar J, Rejon CS, Munafo M, Atwood A, Granger K. O10.4. Latent Inhibition As A Stratification Tool For Schizophrenia Drug Development Schizophrenia Bulletin. 45. DOI: 10.1093/Schbul/Sbz021.252 |
0.34 |
|
| 2019 |
Granger K, Martyn Q, Ryan L, Bransby-Adams K, French V, O’Regan E, Haselgrove M, Moran P. F34. ASSOCIATIVE LEARNING ABNORMALITIES IN PSYCHOSIS Schizophrenia Bulletin. 45: S268-S268. DOI: 10.1093/Schbul/Sbz018.446 |
0.616 |
|
| 2018 |
Cotter J, Muhlert N, Talwar A, Granger K. Examining the effectiveness of acetylcholinesterase inhibitors and stimulant-based medications for cognitive dysfunction in multiple sclerosis: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews. 86: 99-107. PMID 29406017 DOI: 10.1016/J.Neubiorev.2018.01.006 |
0.339 |
|
| 2018 |
Cotter J, Granger K, Backx R, Hobbs M, Looi CY, Barnett JH. Social cognitive dysfunction as a clinical marker: A systematic review of meta-analyses across 30 clinical conditions. Neuroscience and Biobehavioral Reviews. 84: 92-99. PMID 29175518 DOI: 10.1016/j.neubiorev.2017.11.014 |
0.302 |
|
| 2018 |
Cotter J, Granger K, Backx R, Hobbs M, Looi CY, Barnett JH. Social cognitive dysfunction as a clinical marker: A systematic review of meta-analyses across 30 clinical conditions. Neuroscience and Biobehavioral Reviews. 84: 92-99. PMID 29175518 DOI: 10.1016/J.Neubiorev.2017.11.014 |
0.403 |
|
| 2018 |
Granger K, Cotter J, Baker E, Evenden J, Barnett J, Sand M. S74. Exploring Participant-Level Trajectories Of Cognitive Performance Among Patients With Schizophrenia In A Multi-National Trial. Schizophrenia Bulletin. 44. DOI: 10.1093/Schbul/Sby018.861 |
0.429 |
|
| 2018 |
Cotter J, Granger K, Evenden J, Barnett J, Sand M. F74. Clinical Symptoms And Not Objective Cognitive Performance Drive Subjective Cognitive Complaints In Patients With Schizophrenia Schizophrenia Bulletin. 44. DOI: 10.1093/Schbul/Sby017.605 |
0.411 |
|
| 2018 |
Cotter J, Granger K, Barnett J. T79. Affective Face Processing In Schizophrenia: Disorder-Specific Or Transdiagnostic Deficit? Schizophrenia Bulletin. 44. DOI: 10.1093/Schbul/Sby016.355 |
0.328 |
|
| 2016 |
Granger KT, Moran PM, Buckley MG, Haselgrove M. Enhanced latent inhibition in high schizotypy individuals Personality and Individual Differences. 91: 31-39. DOI: 10.1016/J.Paid.2015.11.040 |
0.663 |
|
| 2012 |
Granger KT, Prados J, Young AM. Disruption of overshadowing and latent inhibition in high schizotypy individuals. Behavioural Brain Research. 233: 201-8. PMID 22579971 DOI: 10.1016/j.bbr.2012.05.003 |
0.309 |
|
| Show low-probability matches. |